Zn-MOF模板法制备ZnO/C/SNTs及其药物缓释性能

采用超声法一步合成了SiO₂包覆金属-有机骨架Zn₆(OH)₃(BTC)₃(H₂O)₃] ·7H₂O(Zn-MOF, BTC=1,3,5-均苯三羧酸根)纳米晶, 在N₂保护下, 热解Zn-MOF@SiO₂获得了ZnO/C/SNTs复合物, 进而与布洛芬(HIBU)反应合成药物组装体Zn(IBU)₂/C/SNTs. 通过透射电子显微镜(TEM)、 傅里叶变换红外光谱仪(FTIR)、 高分辨透射电子显微镜(HRTEM)和X射线衍射仪(XRD)对样品的结构和形貌进行表征. 结果显示, Zn-MOF@SiO₂呈棒状, 具有清晰的核/壳结构, 形貌单一, 分散性良好. 煅烧后SNTs结构稳定, 形貌基本不变. 载药实验表明, 药物组装体的载药量为752 mg/g, 并具有良好的pH响应性能.

Synthesis of ZnO/C/SNTs Using Zn-MOF as Template and Their Drug Delivery Ability

Nanocrystallines of metal-organic framework Zn₆(OH)₃(BTC)₃(H₂O)₃] ·7H₂O(Zn-MOF, BTC=benzene-1,3,5-tricarboxylate) coated with SiO₂ nanotubes(SNTs) were synthesized by a simple one-step ultrasonic route. ZnO/C/SNTs hybrid composites were produced by thermolysis of Zn-MOF/SNTs in N₂ environments, then the drug assemblies of Zn(IBU)₂/C/SNTs were synthesized by the reaction of ibuprofen(HIBU) and ZnO/C/SNTs. The morphology and structure of nanoparticle were characterized by transmission electron microscopy(TEM), high resolution transmission electron microscopy(HRTEM), Fourier transform infrared spectrometry(FTIR) and X-ray diffraction(XRD). The results show that the Zn-MOF/SNTs have clear core-shell structure with rod-like shape, same-sized and well-dispersed. The as-prepared SNTs have better structure stability and the morphologies remain unchangeable after calcination. The results demonstrated that the drug loading was about 752 mg/g, and the drug assemblies had an excellent pH responsive behavior.